Iltefat Hamzavi, MD, Department of Dermatology, Henry Ford Medical Center, discusses his recent research letter that addresses the benefits of ruxolitinib cream for the treatment of vitiligo, and highlights the clinically meaningful use of...
Iltefat Hamzavi, MD, Department of Dermatology, Henry Ford Medical Center, discusses his recent research letter that addresses the benefits of ruxolitinib cream for the treatment of vitiligo, and highlights the clinically meaningful use of...
David Rosmarin, MD, vice chair of education and research, assistant professor, Tufts Medical Center, walks through findings from TRuE-V, a phase 3 program designed to investigate ruxolitinib's efficacy and safety in patients with vitiligo.
David Rosmarin, MD, vice chair of education and research, assistant professor, Tufts Medical Center, walks through findings from TRuE-V, a phase 3 program designed to investigate ruxolitinib's efficacy and safety in patients with vitiligo.
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, describes how the atopic dermatitis treatment paradigm has been changing amid increased market competition, as well as where the future of care may be headed.
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, describes how the atopic dermatitis treatment paradigm has been changing amid increased market competition, as well as where the future of care may be headed.
Raj Chovatiya, MD, PhD, director, Center for Eczema and Itch, Northwestern University, offers insight into how social determinants of health affect care access and quality for patients with atopic dermatitis.
Raj Chovatiya, MD, PhD, director, Center for Eczema and Itch, Northwestern University, offers insight into how social determinants of health affect care access and quality for patients with atopic dermatitis.
Raj Chovatiya, MD, PhD, director, Center for Eczema and Itch, Northwestern University, shares how severe atopic dermatitis impacts patients' quality of life, as well as what treatment challenges exist for this patient population.
Raj Chovatiya, MD, PhD, director, Center for Eczema and Itch, Northwestern University, shares how severe atopic dermatitis impacts patients' quality of life, as well as what treatment challenges exist for this patient population.
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, highlights clinical scenarios in which a topical treatment for atopic dermatitis may be most effective.
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, highlights clinical scenarios in which a topical treatment for atopic dermatitis may be most effective.
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, provides an overview of a recently approved treatment for atopic dermatitis.
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, provides an overview of a recently approved treatment for atopic dermatitis.
Gary Owens, MD, president of Gary Owens Associates, shares his thoughts on the challenges of choosing treatment options for patients with atopic dermatitis, and highlights key takeaways for payers from a recent ICER report which compared the...
Gary Owens, MD, president of Gary Owens Associates, shares his thoughts on the challenges of choosing treatment options for patients with atopic dermatitis, and highlights key takeaways for payers from a recent ICER report which compared the...
Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying...
Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying...
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues...
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
